Literature DB >> 16036026

Inhibition of RAAS--when is it too much?

Pablo Navarro1, Robert Moskowitz, Thierry H Le Jemtel.   

Abstract

Deactivation of the renin-angiotensin-aldosterone system (RAAS) is clearly beneficial in patients with recent myocardial infarction and chronic heart failure. Most of the experience with deactivation of the RAAS has been collected in placebo-controlled randomized trials of angiotensin- converting enzyme inhibition (ACEI). The hypothesis that angiotensin receptor blockade may be a better approach to deactivate the RAAS has not survived the test of time. Despite the extensive experience with ACEI and aldosterone receptor blockade in patients with recent myocardial infarction and chronic heart failure, several issues remain unanswered. These are addressed in this review.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 16036026     DOI： 10.1007/s11897-004-0026-3

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN： 1546-9530


  50 in total

1.  Long-term effects of clinical outcome with low and high dose in the Captopril in Heart Insufficient Patients Study (CHIPS).

Authors:  D L Clement; M De Buyzere; M Tomas; G Vanavermaete
Journal:  Acta Cardiol       Date:  2000-02       Impact factor: 1.718

2.  Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.

Authors:  J Malcolm O Arnold; Salim Yusuf; James Young; James Mathew; David Johnstone; Alvaro Avezum; Eva Lonn; Janice Pogue; Jackie Bosch
Journal:  Circulation       Date:  2003-03-11       Impact factor: 29.690

3.  Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure.

Authors:  R Pacher; B Stanek; S Globits; R Berger; M Hülsmann; M Wutte; B Frey; M Schuller; E Hartter; E Ogris
Journal:  Eur Heart J       Date:  1996-08       Impact factor: 29.983

4.  Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.

Authors:  D V Exner; D L Dries; M J Domanski; J N Cohn
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

5.  Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.

Authors:  U P Jorde; P V Ennezat; J Lisker; V Suryadevara; J Infeld; S Cukon; A Hammer; E H Sonnenblick; T H Le Jemtel
Journal:  Circulation       Date:  2000-02-29       Impact factor: 29.690

6.  Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.

Authors:  Maylene Wong; Lidia Staszewsky; Roberto Latini; Simona Barlera; Alberto Volpi; Yann-Tong Chiang; Raymond L Benza; Sidney O Gottlieb; Thomas D Kleemann; Franco Rosconi; Pieter M Vandervoort; Jay N Cohn
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

7.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.

Authors: 
Journal:  Lancet       Date:  1993-10-02       Impact factor: 79.321

8.  Expression of AT2 receptors in the developing rat fetus.

Authors:  E F Grady; L A Sechi; C A Griffin; M Schambelan; J E Kalinyak
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

9.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

Authors:  S Yusuf; B Pitt; C E Davis; W B Hood; J N Cohn
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

10.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.